BMO Capital analyst Gary Nachman maintained a Buy rating on Horizon Therapeutics (NASDAQ:HZNP) on Thursday, setting a price target of $138, which is approximately 24.70% above the present share price of $110.67.
Nachman expects Horizon Therapeutics to post earnings per share (EPS) of $1.44 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Horizon Therapeutics, with an average price target of $135.5.
The analysts price targets range from a high of $155 to a low of $107.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $1.04 billion and a net profit of $331.54 million. The company's market cap is $25.1 billion.
According to TipRanks.com, BMO Capital analyst Gary Nachman is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.8% and a 42.58% success rate.
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.